Subscribe To
Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor
Topline data from the Phase 1 SAD/MAD trial of VTX3232 are expected in H1 2024 ENCINITAS, Calif., June 14, 2023 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that […] The post Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3...
Read More
Content Topics
Ventyx
Biosciences
Announces
Initiation
Dosing
Phase
Trial
Vtx3232
Cns penetrant
Inhibitor
Forex
Posted: Jun 14 2023, 11:00
Author Name: forextv
Views: 101980